Viking Therapeutics, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, the company advances a pipeline targeting obesity, metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), lipid disorders, and rare diseases such as X-linked adrenoleukodystrophy (X-ALD). Its core programs include VK2735, a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist available in subcutaneous and oral formulations for obesity and related metabolic conditions; VK2809, an orally available small molecule selective thyroid hormone receptor beta (TR beta) agonist for MASH, fibrosis, NAFLD, and elevated low-density lipoprotein cholesterol (LDL-C); dual amylin and calcitonin receptor agonists (DACRAs) for obesity; and VK0214, an orally available selective TR beta agonist for X-ALD. Viking Therapeutics operates primarily in the United States with a focus on patients suffering from high unmet needs in metabolic and endocrine diseases, leveraging internal expertise in metabolism to drive innovation across its wholly-owned pipeline. The company's lead candidate, subcutaneous VK2735, advances in Phase 3 VANQUISH-1 and VANQUISH-2 registration trials for obesity in adults with and without type 2 diabetes, following positive Phase 2 VENTURE trial results; the oral formulation of VK2735 progresses in the Phase 2 VENTURE-Oral trial, with enrollment completed and data anticipated in the second half of 2025. VK2809 met primary and secondary endpoints in the Phase 2b VOYAGE trial for biopsy-confirmed MASH and fibrosis, building on prior Phase 2a data showing significant LDL-C and liver fat reductions; VK0214 demonstrated proof-of-concept in a Phase 1b trial for X-ALD by reducing very long-chain fatty acids. Recent developments include the completion of enrollment in the Phase 3 VANQUISH-1 trial for subcutaneous VK2735 in November 2025, alongside plans for a Phase 1 monthly dosing study in the third or fourth quarter of 2025 and an investigational new drug (IND) filing for its amylin agonist program in the fourth quarter of 2025. In March 2025, Viking secured a $150 million multi-year manufacturing agreement with CordenPharma to produce multiple metric tonnes of VK2735 annually, supporting over one billion oral pills or substantial injectable volumes to meet potential commercial demand. Phase 3 trials for subcutaneous VK2735 commenced in the second quarter of 2025, positioning the company to compete in the expanding obesity market dominated by GLP-1-based therapies.
Company News
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Viking Therapeutics Starts Phase III Development of Obesity Pill
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
3 Absurdly Cheap Stocks to Buy Before the End of 2026
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.
Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
VKTX Advances Obesity Program With New Oral Maintenance Study
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Here Are My Top 4 Stocks to Buy in October